Should I buy or sell Horizon Therapeutics Public stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares. View HZNP analyst ratings or view top-rated stocks .

What is Horizon Therapeutics Public's stock price target for 2024?

7 Wall Street research analysts have issued twelve-month target prices for Horizon Therapeutics Public's stock. Their HZNP share price targets range from $110.00 to $125.00. On average, they predict the company's stock price to reach $116.83 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts .

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company had revenue of $945 million for the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.46% and a net margin of 12.02%. The firm's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $1.07 EPS.

What ETFs hold Horizon Therapeutics Public's stock?

ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include IQ Merger Arbitrage ETF (MNA) , First Trust Merger Arbitrage ETF (MARB) , AltShares Merger Arbitrage ETF (ARB) , VictoryShares Nasdaq Next 50 ETF (QQQN) , ProShares Merger ETF (MRGR) , Invesco Nasdaq Biotechnology ETF (IBBQ) , Goldman Sachs Hedge Industry VIP ETF (GVIP) and Strategas Global Policy Opportunities ETF (SAGP) .

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com . Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA) , NVIDIA (NVDA) , OPKO Health (OPK) , Advanced Micro Devices (AMD) , Netflix (NFLX) , Gilead Sciences (GILD) , Tesla (TSLA) , AbbVie (ABBV) , Micron Technology (MU) and PayPal (PYPL) .

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a number of institutional and retail investors. Top institutional investors include Pentwater Capital Management LP (0.00%), Walleye Trading LLC (0.00%), Maven Securities LTD (0.00%), Soros Fund Management LLC (1.44%), Adage Capital Partners GP L.L.C. (1.28%) and Morgan Stanley (1.24%). Insiders that own company stock include Aaron Cox , Andy Pasternak , Barry Moze , Brian K Beeler , Daniel A Camardo , Elizabeth HZ Thompson , Geoffrey M Curtis , Irina Konstantinovsky , Jeffrey W Sherman , Michael A Desjardin , Michael G Grey , Miles W Mchugh , Paul W Hoelscher, Paul W Hoelscher , Sean M Clayton , Timothy P Walbert , Vikram Karnani and William F Daniel . View institutional ownership trends .

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc.. Read More

Horizon Therapeutics Public Stock Price, News & Analysis (NASDAQ:HZNP)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $116.30
▼
$116.30
50-Day Range: $112.60
▼
$116.30
52-Week Range: $60.03
▼
$116.38

Volume: N/A
Average Volume: 2.50 million shs
Market Capitalization: $26.63 billion

P/E Ratio: 62.19
Dividend Yield: N/A
Price Target: $116.83

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media Sustainability

Horizon Therapeutics Public MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 0.5% Upside
$116.83 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 35.08%
From $4.19 to $5.66 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

842nd out of 949 stocks

Pharmaceutical Preparations Industry

395th out of 435 stocks

1.0

Analyst's Opinion

Consensus Rating
Horizon Therapeutics Public has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $116.83, Horizon Therapeutics Public has a forecasted upside of 0.5% from its current price of $116.30.
Amount of Analyst Coverage
Horizon Therapeutics Public has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for HZNP.

0.0

Dividend Strength

Dividend Yield
Horizon Therapeutics Public does not currently pay a dividend.
Dividend Growth
Horizon Therapeutics Public does not have a long track record of dividend growth.

3.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Horizon Therapeutics Public has received a 34.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Nonsteroidal anti-inflammatory drugs", "Pegloticase", "Cysteamine", "Sodium phenylbutyrate", and "Inebilizumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Horizon Therapeutics Public is -2.61.

0.6

News and Social Media Coverage

Search Interest
1 people have searched for HZNP on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Horizon Therapeutics Public to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Horizon Therapeutics Public insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.20% of the stock of Horizon Therapeutics Public is held by insiders.
Percentage Held by Institutions
80.37% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Horizon Therapeutics Public are expected to grow by 35.08% in the coming year, from $4.19 to $5.66 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Horizon Therapeutics Public is 62.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.98.
Price to Earnings Ratio vs. Sector
The P/E ratio of Horizon Therapeutics Public is 62.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 113.00.
Price to Earnings Growth Ratio
Horizon Therapeutics Public has a PEG Ratio of 3.96. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Horizon Therapeutics Public has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Horizon Therapeutics Public Stock (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

November 16, 2023 | msn.com

Nasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business Combination

October 24, 2023 | chicago.suntimes.com

Horizon Therapeutics cut jobs in Deerfield after Amgen acquisition

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

October 24, 2023 | msn.com

350 Horizon Therapeutics workers to be laid off, mostly from Deerfield offices, following acquisition by Amgen

October 6, 2023 | finance.yahoo.com

Rule 17(e) Announcement - Horizon Therapeutics plc

October 5, 2023 | stocknews.com

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

October 5, 2023 | stockhouse.com

Rule 17(d) Announcement - Horizon Therapeutics plc

October 5, 2023 | finance.yahoo.com

Rule 17(d) Announcement – Horizon Therapeutics plc

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

October 2, 2023 | finance.yahoo.com

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

September 26, 2023 | benzinga.com

Board Member at Horizon Therapeutics Exercises Options Worth $2.31M

September 26, 2023 | finance.yahoo.com

Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry

September 19, 2023 | finance.yahoo.com

Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List

September 19, 2023 | finance.yahoo.com

Health care: FTC Chair Lina Khan to crack down on 'below radar' deals

September 13, 2023 | finance.yahoo.com

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata

September 5, 2023 | finance.yahoo.com

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

September 4, 2023 | benzinga.com

Here's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth Today

September 1, 2023 | finanznachrichten.de

Horizon Therapeutics plc and Amgen: Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

August 28, 2023 | finance.yahoo.com

FTC suspends challenge to Amgen-Horizon Therapeutics deal

August 26, 2023 | reuters.com

US FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon Therapeutics

August 23, 2023 | finance.yahoo.com

Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups

August 16, 2023 | seekingalpha.com

Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?

August 16, 2023 | seekingalpha.com

Improved Outlook For Horizon Therapeutics And Amgen

August 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB)

August 9, 2023 | markets.businessinsider.com

Horizon Therapeutics (HZNP) Receives a Hold from H.C. Wainwright

August 8, 2023 | finance.yahoo.com

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results

August 4, 2023 | finance.yahoo.com

Amgen raises full-year earnings and revenue outlook

See More Headlines

Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/08/2023
Today: 11/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:HZNP
CUSIP: 44047T10
CIK: 1492426
Web: www.horizontherapeutics.com
Phone: (531) 772-2100
Fax: 224-383-3001
Employees: 2,115
Year Founded: 2008

Price Target and Rating

Average Stock Price Target: $116.83
High Stock Price Target: $125.00
Low Stock Price Target: $110.00
Potential Upside/Downside: +0.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.87
Trailing P/E Ratio: 62.19
Forward P/E Ratio: 27.76
P/E Growth: 3.96
Net Income: $521.48 million
Net Margins: 12.02%
Pretax Margin: 12.18%
Return on Equity: 20.46%
Return on Assets: 11.52%

Debt

Debt-to-Equity Ratio: 0.48
Current Ratio: 4.27
Quick Ratio: 4.09

Sales & Book Value

Annual Sales: $3.63 billion
Price / Sales: 7.34
Cash Flow: $7.05 per share
Price / Cash Flow: 16.49
Book Value: $22.38 per share
Price / Book: 5.20

Miscellaneous

Outstanding Shares: 228,990,000
Free Float: 223,957,000
Market Cap: $26.63 billion
Optionable: Optionable
Beta: 1.03

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Timothy P. Walbert (Age 56)
Chairman, Pres & CEO
Comp: $3.5M
Mr. Aaron L. Cox (Age 40)
Exec. VP of Fin. & CFO
Comp: $1.36M
Mr. Sean M. Clayton J.D. (Age 44)
Exec. VP & Gen. Counsel
Comp: $7.03M
Mr. Andy Pasternak (Age 52)
Exec. VP & Chief Strategy Officer
Comp: $1.4M
Dr. Elizabeth H.Z. Thompson Ph.D. (Age 48)
Exec. VP of R&D
Comp: $3.66M
Mr. Patrick McIlvenny (Age 44)
Sr. VP & Chief Accounting Officer
Ms. Tina E. Ventura
Sr. VP & Chief Investor Relations Officer
Mr. Geoffrey M. Curtis (Age 48)
Exec. VP of Corp. Affairs & Chief Communications Officer
Ms. Keli Walbert
Exec. VP & Chief Marketing Officer
Ms. Jane Gonnerman
Sr. VP of Corp. Devel. & Chief of Staff, Office of the CEO

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Horizon Therapeutics Public Stock? HZNP Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Horizon Therapeutics Public was last updated on Tuesday, November 28, 2023 at 1:26 PM.

Pros

Here are some ways that investors could benefit from investing in Horizon Therapeutics Public Limited:

The stock price of Horizon Therapeutics Public Limited has been steadily increasing in recent periods, indicating potential growth and positive investor sentiment.
Horizon Therapeutics Public Limited has recently launched a new product, which has received positive reviews and is expected to contribute to the company's revenue growth.
The company has a strong financial position, with a healthy balance sheet and positive cash flow, providing stability and potential for future investments and acquisitions.
Horizon Therapeutics Public Limited has a diversified product portfolio, reducing the risk associated with relying on a single product or market segment.
The company has a robust research and development pipeline, indicating potential for future product innovations and market expansion.

Cons

Investors should be bearish about investing in Horizon Therapeutics Public Limited for these reasons:

The stock price of Horizon Therapeutics Public Limited has experienced volatility in recent periods, which may indicate uncertainty and potential risks for investors.
The pharmaceutical industry is highly regulated, and changes in regulations or government policies could impact the company's operations and financial performance.
Competition in the pharmaceutical industry is intense, and Horizon Therapeutics Public Limited may face challenges in maintaining market share and pricing power.
The company's success is dependent on the successful development and commercialization of its pipeline products, which may involve significant research and development costs and regulatory hurdles.
Investing in the stock market always carries inherent risks, and investors should carefully consider their risk tolerance and investment objectives before investing in Horizon Therapeutics Public Limited.

HZNP Stock Analysis - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings or view top-rated stocks.
What is Horizon Therapeutics Public's stock price target for 2024?: 7 Wall Street research analysts have issued twelve-month target prices for Horizon Therapeutics Public's stock. Their HZNP share price targets range from $110.00 to $125.00. On average, they predict the company's stock price to reach $116.83 in the next year. This suggests a possible upside of 0.5% from the stock's current price.
View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts.
How were Horizon Therapeutics Public's earnings last quarter?: Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company had revenue of $945 million for the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.46% and a net margin of 12.02%. The firm's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $1.07 EPS.
What ETFs hold Horizon Therapeutics Public's stock?: ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), VictoryShares Nasdaq Next 50 ETF (QQQN), ProShares Merger ETF (MRGR), Invesco Nasdaq Biotechnology ETF (IBBQ), Goldman Sachs Hedge Industry VIP ETF (GVIP) and Strategas Global Policy Opportunities ETF (SAGP).

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?: 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Horizon Therapeutics Public own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).
Who are Horizon Therapeutics Public's major shareholders?: Horizon Therapeutics Public's stock is owned by a number of institutional and retail investors. Top institutional investors include Pentwater Capital Management LP (0.00%), Walleye Trading LLC (0.00%), Maven Securities LTD (0.00%), Soros Fund Management LLC (1.44%), Adage Capital Partners GP L.L.C. (1.28%) and Morgan Stanley (1.24%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends.
Does Horizon Therapeutics Public have any subsidiaries?: The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..
Read More

This page (NASDAQ:HZNP) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Horizon Therapeutics Public Stock Price, News & Analysis (NASDAQ:HZNP)

Horizon Therapeutics Public MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Horizon Therapeutics Public Stock (NASDAQ:HZNP)

HZNP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy Horizon Therapeutics Public Stock? HZNP Pros and Cons Explained

Pros

Cons

HZNP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™